Embark on a captivating journey with our distinguished neurology faculty as they delve into the revolutionary world of FDA-approved monoclonal antibody therapies targeting β-amyloid in the treatment of Alzheimer disease (AD). Uncover clinical efficacy, safety nuances, and differences between these newer disease-modifying agents compared to older medications used for AD. Gain insights on identifying which patients are most likely to benefit from these cutting-edge agents and who warrants referral to a dementia specialist. Elevate your understanding of AD treatment and join the forefront of medical innovation.